Sie befinden sich hier
Inhalt
GSK- ASCEND-D / ASCEND-ND
Prüfplancode: 200808
EUDRA CT: 2016-000542-65 Phase IIIA
Prüfplancode: 200807
EUDRA CT: 2016-000541-31 Phase IIIA
Compound Number:
- GSK1278863
- GSK1278863
ASCEND-ND (200808):
A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated and chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
ASCEND-D (200807):
A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated and chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.
Sponsor:
GlaxoSmithKline GmbH & Co.KG; UK
Start: Mai 2017
PI: PD Dr. med. U. Benck
SI: Dr. med. M. Mircheva, PD Dr. med. A. Kälsch
everlinQ endoAVF EU Study
Protokoll Nummer: CD-0018
Prospective, multi-center study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for hemodialysis.
Sponsor:
TVA Medical, Inc., USA
Start: Februar 2016
PI: PD Dr. med. U. Benck
SI : PD Dr. med. A. Kälsch
CHORUS
Protocol ISN: 506-MA-1002
European Multicentre Kidney Transplant Advagraf Conversion Registry. A non-interventional post-autorisation study (PAS).
Sponsor:
Astellas Pharma Europe Ltd.
Start: Januar 2015
PI: Prof. Dr. med. B. Krämer
SI: Prof. Dr. med. B. Krüger
ADDRESS
Prüfplancode: PMR – EC – 1213
EUDRA CT : N/A Phase IV
A long-term follow-up of adult kidney and liver allograft recipients previously enrolled into a Tacrolimus (Advagraf) Trial. A multicenter, non-interventional, post authorization study (PAS).
Sponsor:
Astellas Pharma Europe B. V. Niederlande
Start: September 2014
PI: Prof. Dr. med. B. Krüger
SOLKID
Studiencode: SolKiD
Untersuchung der körperlichen und psychosozialen Folgen nach Lebendnieren-Spende; Eine multizentrische Kohortenstudie ( Safty of Living Kidney Donors).
Sponsor:
Westfälische Wilhelms Universität, Medizinische Fakultät Münster
Start: März 2014
PI: Prof. Dr. med. Bernd Krüger
BMS Studie
Prüfplancode: IM103-116
EUDRA CT: 2012-001314-42 Phase II
Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix (belatacept)-based Immunosuppression.
Sponsor:
Bristol-Myers Squibb
Start: September 2013
PI: Prof. Dr. med. B. Krüger
SI: PD Dr. med. U. Benck
Diacore
A cohorte study of patients with diabetes mellitus type 2 Studie zur Erforschung möglicher Ursachen der Nierenbeteiligung bei Patienten mit Diabetes mellitus Typ2.
Sponsor:
KfH-Stiftung-Präventivmedizin e.V.
Start:
Ende:
PI: Prof. Dr. med. Krämer
SI: Dr. med. A.Lammert
Kontextspalte
Sprechstunden und Termine
Organspende
Ausgezeichnete Forschung
Spenden
Unterstützen Sie die Patientenversorgung an der V. Medizinischen Klinik.